GTPase, IMAP family member 3 pseudogeneGenealiases: GIMAP3 · IAN4P
Q-omics provides the consensus-scored GIMAP3P profile across patient tissues and cancer cell-line models. GIMAP3P expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, GIMAP3P is differentially expressed in 9, with the highest sampling consensus in KIRP. Additionally, GIMAP3P RNA expression shows 12,410 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRP, and LSCC as cancer lineages where GIMAP3P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GIMAP3P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GIMAP3P survival associations across molecular data types. GIMAP3P RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GIMAP3P RNA expression–survival associations across cancer types. High GIMAP3P expression shows favorable associations in BLCA, HNSC, BRCA, SKCM, OV and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify BLCA as the clearest survival context for GIMAP3P RNA expression.
This table summarizes GIMAP3P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GIMAP3P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GIMAP3P shows lower tumor expression in KIRP, LUAD, LUSC, BRCA, UCEC and KICH. The KIRP box plot shows higher GIMAP3P RNA expression in normal versus tumor tissue (log2 FC = −0.182, t-test p < 0.001).
This table shows molecular features associated with GIMAP3P in patient tissues and cancer cell lines. In patient samples, GIMAP3P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
